JP2023532536A5 - - Google Patents

Info

Publication number
JP2023532536A5
JP2023532536A5 JP2022581521A JP2022581521A JP2023532536A5 JP 2023532536 A5 JP2023532536 A5 JP 2023532536A5 JP 2022581521 A JP2022581521 A JP 2022581521A JP 2022581521 A JP2022581521 A JP 2022581521A JP 2023532536 A5 JP2023532536 A5 JP 2023532536A5
Authority
JP
Japan
Prior art keywords
seq
composition
item
mirna inhibitor
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022581521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532536A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/055890 external-priority patent/WO2022003608A1/en
Publication of JP2023532536A publication Critical patent/JP2023532536A/ja
Publication of JP2023532536A5 publication Critical patent/JP2023532536A5/ja
Pending legal-status Critical Current

Links

JP2022581521A 2020-07-01 2021-07-01 miRNA-485ハンチントン病の阻害剤 Pending JP2023532536A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047090P 2020-07-01 2020-07-01
US63/047,090 2020-07-01
PCT/IB2021/055890 WO2022003608A1 (en) 2020-07-01 2021-07-01 Mirna-485 inhibitor for huntington's disease

Publications (2)

Publication Number Publication Date
JP2023532536A JP2023532536A (ja) 2023-07-28
JP2023532536A5 true JP2023532536A5 (cg-RX-API-DMAC7.html) 2024-07-09

Family

ID=79315650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022581521A Pending JP2023532536A (ja) 2020-07-01 2021-07-01 miRNA-485ハンチントン病の阻害剤

Country Status (9)

Country Link
US (1) US20230304014A1 (cg-RX-API-DMAC7.html)
EP (1) EP4175675A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023532536A (cg-RX-API-DMAC7.html)
KR (1) KR20230031852A (cg-RX-API-DMAC7.html)
CN (1) CN115867290A (cg-RX-API-DMAC7.html)
AU (1) AU2021302972A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022027040A2 (cg-RX-API-DMAC7.html)
CA (1) CA3184043A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022003608A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240154159A (ko) 2023-04-17 2024-10-25 재단법인 아산사회복지재단 miR-223을 유효성분으로 포함하는 간 손상 예방 또는 치료용 조성물
CN116694562B (zh) * 2023-08-03 2023-11-03 四川大学华西医院 一种BMEC释放的sEV、其制备方法、用途及药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2205737T3 (da) * 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
WO2018139819A1 (ko) * 2017-01-26 2018-08-02 주식회사 바이오오케스트라 마이크로 rna를 이용한 뇌 질환 예방 또는 치료 용도
CN115461085A (zh) * 2020-02-07 2022-12-09 生物欧赛加有限责任公司 miRNA-485抑制剂用于治疗tau蛋白病的用途
US20230241118A1 (en) * 2021-10-20 2023-08-03 University Of Rochester Rejuvenation treatment of age-related white matter loss

Similar Documents

Publication Publication Date Title
JP2022538868A5 (cg-RX-API-DMAC7.html)
Yang et al. Efficient cytosolic delivery of siRNA using HDL‐mimicking nanoparticles
JP4613011B2 (ja) invivo遺伝子伝達を改善する医薬組成物
Chen et al. A review of gene therapy delivery systems for intervertebral disc degeneration
JP2023513188A5 (cg-RX-API-DMAC7.html)
JP2023513190A5 (cg-RX-API-DMAC7.html)
Oryan et al. Basic concepts, current evidence, and future potential for gene therapy in managing cutaneous wounds
Dar et al. Systemic delivery of stable siRNA-encapsulating lipid vesicles: optimization, biodistribution, and tumor suppression
Sasaki et al. Alpha-dystroglycan binding peptide A2G80-modified stealth liposomes as a muscle-targeting carrier for Duchenne muscular dystrophy
JP2024501437A5 (cg-RX-API-DMAC7.html)
Ouyang et al. A biomimic reconstituted high-density-lipoprotein-based drug and p53 gene co-delivery system for effective antiangiogenesis therapy of bladder cancer
JP2023513189A5 (cg-RX-API-DMAC7.html)
Pan et al. In vitro gene transfection in human glioma cells using a novel and less cytotoxic artificial lipoprotein delivery system
IL316806A (en) Compositions and methods for treating monogenic neurodevelopmental disorder
Baradaran et al. A novel method for the development of plasmid DNA-loaded nanoliposomes for cancer gene therapy
US12582669B2 (en) Composition controlling pharmacokinetics in the body
JP7481694B2 (ja) 核酸送達複合体
JP2024503303A5 (cg-RX-API-DMAC7.html)
Verma et al. < p style=
CN107823652B (zh) 一种长循环自组装复合纳米制剂、其制备方法及其用途
US12441999B2 (en) Hybrid htiRNA/nanoparticle complex and use thereof for treating a disease of the digestive system
KR100986604B1 (ko) 신규한 아미노지질을 함유하는 에스아이알엔에이 수송용 유전자 조성물 및 제조방법
JP2023522402A5 (cg-RX-API-DMAC7.html)
US20250146001A1 (en) Compositions and Methods for Enhancing AAV Therapy and Decreasing Tropism of AAV to the Liver
US20260078381A1 (en) Methods for Directing Lipid Nanoparticles in Vivo